Vincent Bivins, MD
Urology · Homewood, ALNPI 1609850619
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 47.4% of the total. Among urology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $257.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$55K
- Urogen Pharma, Inc.$10K
- Johnson & Johnson$10K
- Bayer$5K
- Metuchen Pharmaceuticals$5K
- Boston Scientific$3K
- plus $28K from 45 others
Across 74 payments — averaging $15,469 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$938K
- Myriad Genetic Laboratories, Inc.$87K
- Pfizer$77K
- Urogen Pharma, Inc.$43K
What the payments were for
- Consulting fees$23,57720%
- Speaking & faculty fees$66,70657%
- Grants$2,5002%
- Travel & lodging$9,3818%
- Food & beverage$14,41712%
- Education$3000%
- Gifts$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,904 in reported general payments places this provider in the 95th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 42 | $601,222 |
| OrgovyxRelugolix | 150 | $394,362 |
| ErleadaApalutamide | 18 | $256,838 |
| NubeqaDarolutamide | 14 | $186,591 |
| Abiraterone Acetate | 55 | $96,883 |
| MyrbetriqMirabegron | 109 | $69,438 |
| GemtesaVibegron | 64 | $51,382 |
| ElmironPentosan Polysulfate Sodium | 13 | $12,854 |
| XyostedTestosterone Enanthate | 11 | $7,995 |
| Tamsulosin Hcl | 379 | $4,181 |
| Silodosin | 30 | $2,974 |
| Testosterone Cypionate | 119 | $2,958 |
| Dutasteride | 77 | $2,835 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 80 | $1,882 |
| Ciprofloxacin Hcl | 253 | $1,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $2,870 | $670,660151 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $627 | $445,744214 claims |
| Johnson & JohnsonErleada | $10,251 | $256,83818 claims |
| BayerNubeqa | $4,852 | $186,59114 claims |
| Antares Pharma, Inc.Xyosted | $429 | $7,99511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 179 urology providers in Alabama.
Other urology in Homewood
- Brian ChristineHomewood$215K
- Rachel EngelbergHomewood$61K
- Rupa KitchensHomewood$14K
- Jared CoxHomewood$12K
- Brian WadeHomewood$9K
- Donald BraggHomewood$8K
- Tyler PostonHomewood$6K
- Paula RookisHomewood$6K
- Leon HamrickHomewood$5K
- Thomas ChiBirmingham$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.